Chest
-
Tobacco Cessation and Prevention PostersSESSION TYPE: Poster PresentationsPRESENTED ON: Saturday, March 22, 2014 at 01:15 PM - 02:15 PMPURPOSE: This study investigates the role of proinflammatory monocytes recruited from blood and recovered in bronchoalveolar lavage (BAL) fluid in mediating the lung damage in a model of acute cigarette smoke (CS)-induced lung inflammation in two strains of mice with different susceptibility to develop emphysema. ⋯ The following authors have nothing to disclose: Sandra Pérez-Rial, Raúl Terrón-Expósito, Álvaro Girón-Martínez, Nicolás Mangado, Germán Peces-BarbaNo Product/Research Disclosure Information.
-
Transplantation PostersSESSION TYPE: Poster PresentationsPRESENTED ON: Saturday, March 22, 2014 at 01:15 PM - 02:15 PMPURPOSE: We developed a protocol to procure human lungs from victims of cardiac arrest in an urban county in North Carolina by co-operation with Emergency Medical Services (EMS), our organ procurement organization (OPO), and our hospital, and evaluate them for transplant suitability with EVLP (XVIVO™). ⋯ Thomas Egan: Other: Received donations-in-kind (equipment and supplies) from XVIVO for this research, Shareholder: and Founder, X-In8 Biologicals Corporation, deveoping products to reduce ischemia-reperfusion injury for transplant. My spouse is paid hourly for bookkeeping of NIH-funded grants., Fiduciary position (of any organization, association, society, etc, other than ACCP: President and founder of Lung Banks of America, a 501(c)3 Corporation whose mission is to promote lung retrieval from non-heart-beating donors. I am not paid. My spouse will be paid to administer a subcontract on a NIH-funded subcontract as Sect-Treasurer., Grant monies (from sources other than industry): This work was supported by NIH grant 1RC2HL101641-01, which paid part of my salary John Blackwell: Other: My PI and my Department received donations-in-kind (equipment and supplies) from XVIVO for this project, Grant monies (from sources other than industry): This work was supported by NIH grant 1RC2HL101641-01, which paid part of my salary Lolita Forrest: Other: My PI and my Department received donations-in-kind (equipment and supplies) from XVIVO for this project, Grant monies (from sources other than industry): This work was supported by NIH grant 1RC2HL101641-01, which paid part of my salary William Simmons: Other: My PI and my Department received donations-in-kind (equipment and supplies) from XVIVO for this project, Grant monies (from sources other than industry): This work was supported by NIH grant 1RC2HL101641-01, which paid part of my salary Katherine Birchard: Grant monies (from sources other than industry): This work was supported by NIH grant 1RC2HL101641-01, which paid part of my salary William Funkhouser: Grant monies (from sources other than industry): This work was supported by NIH grant 1RC2HL101641-01, which paid part of my salary Boming Dong: Other: My PI and my Department received donations-in-kind (equipment and supplies) from XVIVO for this project, Grant monies (from sources other than industry): This work was supported by NIH grant 1RC2HL101641-01, which paid part of my salary Staci Beamer: Other: My PI and my Department received donations-in-kind (equipment and supplies) from XVIVO for this project Sheakar Reddy: Grant monies (from sources other than industry): This work was supported by NIH grant 1RC2HL101641-01, which paid part of my salary Nissa Casey: Grant monies (from sources other than industry): This work was supported by NIH grant 1RC2HL101641-01, which paid part of my salary The following authors have nothing to disclose: J Brent Meyers, Michael Bachman, Ginger Delario, Danielle NiedfeldtEx-vivo lung perfusion (EVLP) is not approved by the FDA in humans for transplant. EVLP of lungs retrieved after death is also not approved for use in humans. The presenter has an IDE from the FDA and UNC IRB approval to offer suitable lungs retrieved after death assessed by EVLP for transplant to consented patients.
-
Non-Invasive VentilationSESSION TYPE: Slide PresentationsPRESENTED ON: Saturday, March 22, 2014 at 12:15 PM - 01:15 PMPURPOSE: Evaluation of non invasive ventilation (NIV) instituted for the first time in hospitalizations of patients with exacerbation of chronic obstructive pulmonary disease (COPD) associated with acute hypercapnic respiratory failure (AHRF) and its prognosis. ⋯ The following authors have nothing to disclose: Maria João Oliveira, Margarida Dias, Inês Franco, Sara CondeNo Product/Research Disclosure Information.
-
Infectious Disease Case Reports Posters IIISESSION TYPE: Case Report PosterPRESENTED ON: Sunday, March 23, 2014 at 01:15 PM - 02:15 PMINTRODUCTION: Falciparum Malaria is associated with transient immunosuppression resulting in disseminated fungal infections like aspergillosis. Ineffective phagocyotosis by alveolar macrophages was implicated as the pathogenetic mechanism leading to disseminated fungal infections. So far 4 cases were reported in the literature of severe falciparum malaria associated with disseminated aspergillosis. We present the first documented case of malaria observed in different stages on bronchoalveolar lavage with underlying disseminated aspergillosis. ⋯ The following authors have nothing to disclose: Suresh UppalapuNo Product/Research Disclosure Information.
-
Respiratory Infections PostersSESSION TYPE: Poster PresentationsPRESENTED ON: Saturday, March 22, 2014 at 01:15 PM - 02:15 PMPURPOSE: Linezolid is a novel oxazolidine antibiotic with activity against methicillin-resistant Staphylococcus aureus (MRSA), Vancomycin-resistant enterococci (VRE) and penicillin-resistant Streptococcus pneumonia, besides activity against Clostridium perfingens, Clostridium difficle, Peptostreptococcus spp., and Bacteroides fragilis. With the emergence of multi-drug resistant organism efforts have been directed towards antibiotics stewardship. We conducted a retrospective chart review in a small community hospital to evaluate the pattern of use of linezolid based on institutional guidelines. ⋯ The following authors have nothing to disclose: George Udeani, Salim SuraniNo Product/Research Disclosure Information.